Philips Receives FDA Approval for Novel Rembra Imaging Technology
Philips has received 510(k) clearance from the US Food and Drug Administration for its Rembra platform, which includes the Rembra CT, Rembra RT, and Areta RT systems.
The newly approved solutions are designed to support faster and more accurate CT imaging in frontline healthcare settings and cancer treatment planning.
The Rembra platform has been developed to help healthcare providers manage growing imaging demand and increasing clinical complexity.
The systems aim to improve workflow efficiency, imaging speed, and access to high-quality scans while supporting confident clinical decision-making.
Rembra CT features an 85 cm bore and is designed for high-volume imaging in emergency departments, critical care units, and interventional settings. The system supports rapid image acquisition and reconstruction, helping clinicians deliver timely diagnoses in urgent situations.
Rembra RT and Areta RT extend these imaging capabilities into radiation therapy. The systems offer advanced 4DCT imaging and a wide field of view to support more accurate tumour targeting and treatment planning while helping to protect surrounding healthy tissue.
According to Philips, the platform creates a connected CT imaging ecosystem that supports patient care from emergency diagnosis to precision-guided cancer therapy.
The FDA clearance further strengthens the company’s CT imaging portfolio and supports more connected and efficient healthcare delivery.
